Would you like to help researchers learn more about a treatment for Crohn’s Disease?

UVA Tracking #
Principal Investigator
Esteban Figueroa
Tammi Reynolds
Contact Email
Contact Phone
Official Trial Title
A Phase 2b Randomized, Double-blind, Active- and Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy and Safety of Induction and Maintenance Combination Therapy with Guselkumab and Golimumab in Participants with Moderately to Se
Study Description

The Gastroenterology Department seeks adults ages 18-65 who have been diagnosed with moderately to severe Crohn’s Disease of >3 months duration, to test if a combination of two market-approved medications are safe and effective for the treatment of CD.

The study involves a six week screening period with tests and health assessments, including a colonoscopy. If you qualify you would receive subcutaneous study medication or placebo, with 13 clinic visits every four weeks, 2 phone visits and 2 colonoscopies. After this first phase, if you qualify and choose to participate, you may enter a long-term extension that would last approximately 4 years.

Study-related procedures, exams and medication are provided at no cost.


$167 for each completed study visit.